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A diverse spectrum of anthropogenic mole-
cules is found in the environment, including
chemicals introduced deliberately as well as
unintended by-products of human activity.
Through diligent monitoring, we are learn-
ing the identity, distribution, extent, and
environmental persistence of these chemicals.
To provide a reliable evaluation of the risk
presented by these compounds, information
about the speciﬁc molecules is required. This
includes knowledge of the interaction of the
chemicals with the environment and the
effects of the chemicals or their successors on
human health and ecologic systems.
The health and environmental effects of a
chemical derive from a continuum of processes
that proceed from the source of a chemical or
its predecessors to a set of outcomes. However,
it is often convenient to consider each process
in the continuum as a discrete entity [U.S.
Environmental Protection Agency (EPA)
2003]. Ideally, a risk assessment uses informa-
tion relative to the specific chemical being
considered. However, often the potential
effects of a chemical must be evaluated when
some relevant elements of the preferred data
matrix are missing. In these situations, an esti-
mate is derived by extrapolating from existing
information.
Various approaches, including computa-
tional methods, have been developed to model
these discrete steps in the source-to-outcome
paradigm. These models provide approxima-
tions of the missing experimental information
and a measure of the impact of speciﬁc miss-
ing data on the evaluation of risk. The mod-
els use existing information and can suggest
new experiments. As a result, the source-to-
outcome continuum becomes populated with
information that includes experimental data,
model-derived data, and connection models.
The toxicant–target paradigm is a computa-
tional approach that employs molecular model-
ing methods to estimate relevant interactions
and to populate the outcomes side of the
source-to-outcome continuum.
The Toxicant–Target Paradigm
The differential step in many mechanisms of
toxicity may be generalized as the interaction
between a small molecule (a toxicant) and
one or more macromolecular targets. Targets
include genetic material, receptors, transport
molecules, and enzymes. In addition, other
targets for toxicity could conceptually be
described. The difference in activity observed
between chemicals acting through the same
biologic mode of action may then be under-
stood as differences between their interactions
with putative targets.
Some molecular modeling methods have
been developed speciﬁcally to study interactions
of this type and are commonly employed for
the discovery of novel pharmaceutical agents
(Coupez and Lewis 2006; Sousa et al. 2006).
These methods can estimate the capacity of a
chemical to interact with a speciﬁc target and
cause a biologic effect. In the context of esti-
mating chemical toxicity, this approach can
yield predictions of the potential biologic
activity. These molecular modeling tools can
inform testing strategies or provide elements
in a scheme for estimating toxicity that also
include experimental results.
Molecular Modeling in
Computational Toxicology:
Probing Toxicant–Target
Structure
The toxicant–target paradigm can be used to
develop models for predicting chemical toxic-
ity. These models are composed of approxi-
mate mathematical descriptions of the
underlying physics and chemistry governing
the behavior of the interacting molecules.
These descriptions and their computational
implementations construct a bridge between
the information domains of experimental bio-
molecular structure and biologic effects.
Figure 1 depicts how molecular modeling can
be used to estimate chemical toxicity via the
toxicant–target paradigm.
Experimental information is used to pro-
vide a putative list of potential macromolecu-
lar targets related to chemical toxicity. For
some of these targets, structural information
is available or may be inferred from similar
structures via homology modeling (Hillisch
et al. 2004). The specific interactions
between potential toxicants and the struc-
tures of known targets may be modeled via
Environmental Health Perspectives • VOLUME 116 | NUMBER 5 | May 2008 573
Commentary
Address correspondence to M.A. Pasquinelli, North
Carolina State University, Fiber and Polymer
Science/Department of TECS, Campus Box 8301,
2401 Research Dr., Raleigh, NC 27695 USA.
Telephone: (919) 515-9426. Fax: (919) 515-6532.
E-mail: Melissa_Pasquinelli@ncsu.edu
During a portion of this work, M-R.G. was sup-
ported by National Health and Environmental Effects
Research Laboratory-Department of Environmental
Sciences and Engineering Training Agreement EPA
CT829471.
This work was reviewed by the U.S. Environmental
Protection Agency and approved for publication but
does not necessarily reﬂect ofﬁcial agency policy.
The authors declare they have no competing
ﬁnancial interests.
Received 16 November 2007; accepted 1 February
2008.
Computational Molecular Modeling for Evaluating the Toxicity 
of Environmental Chemicals: Prioritizing Bioassay Requirements
James R. Rabinowitz, Michael-Rock Goldsmith, Stephen B. Little, and Melissa A. Pasquinelli
National Center for Computational Toxicology, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, USA
BACKGROUND: The human health risk from exposure to environmental chemicals often must be
evaluated when relevant elements of the preferred data are unavailable. Therefore, strategies are
needed that can predict this information and prioritize the outstanding data requirements for the
risk evaluation. Many modes of molecular toxicity require the chemical or one of its biotransforma-
tion products to interact with speciﬁc biologic macromolecules (i.e., proteins and DNA). Molecular
modeling approaches may be adapted to study the interactions of environmental chemicals with
biomolecular targets. 
OBJECTIVE: In this commentary we provide an overview of the challenges that arise from applying
molecular modeling tools developed and commonly used for pharmaceutical discovery to the prob-
lem of predicting the potential toxicities of environmental chemicals. 
DISCUSSION: The use of molecular modeling tools to predict the unintended health and environ-
mental consequences of environmental chemicals differs strategically from the use of the same tools
in the pharmaceutical discovery process in terms of the goals and potential applications. It also
requires consideration of the greater diversity of chemical space and binding afﬁnity domains than
is covered by pharmaceuticals. 
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ate the risk to human health and the environment as a result of exposure to environmental chemicals.
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gies to the particular challenges presented by environmental chemical interactions make them even
more effective. 
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In the absence of speciﬁc structural infor-
mation about the targets, an alternative is to
employ a ligand-based, cheminformatics strat-
egy. This method derives relationships among
various attributes of a database of ligands and
known target-based activities. The attributes
of the ligand may be simple or complex struc-
tural descriptions and properties that are
either measured or derived computationally
(Tong et al. 1997; Waller et al. 1996). Note
that these cheminformatics methods have also
been applied to predict chemical toxicity
without direct consideration of a target
(Prathipati et al. 2007), but methods of this
type are not the primary subject of this report.
With both the structural bioinformatics
and cheminformatics approaches, predictive
models are developed and tested with experi-
ments. A feedback process may be used to
improve the quality of the predictions. In
addition, these prediction tools can be used to
identify important missing experimental infor-
mation and relevant bioassays or properties
that are currently unavailable. The underlying
mechanism of action determines the range of
applicability of the model. In order to use this
approach as an element in a toxicity screen or
for developing bioassay strategies, a number of
choices must be made.
To a large extent, the pharmaceutical
industry has driven recent advances in the
design of molecular modeling tools for study-
ing the interactions between a small molecule
and a complex macromolecule (Jorgensen
2004). One approach for the discovery of
leads for developing novel pharmaceutical
agents employs computational “docking” of
each member of a chemical library to macro-
molecular targets that are chosen for potential
therapeutic benefit. Molecular docking is
designed to simulate the binding feasibility
and afﬁnity of small molecules to protein tar-
gets (Abagyan and Totrov 2001; Halperin
et al. 2002). A docking calculation generates a
variety of poses of a small molecule within a
“binding region” of the macromolecular tar-
get, and typically includes ligand flexibility
(Sousa et al. 2006). At times, some form of
macromolecular flexibility (Carlson 2002) is
also included. An important component of the
docking simulation is to identify the potential
binding sites within a macromolecular target.
These sites could be an interior pocket or an
indentation on the macromolecular surface
(Huang and Schroeder 2006).
The calculation of a score assesses the
potential relevance of each docking pose.
Functions used for scoring poses typically
take into account geometric shape comple-
mentarity as well as the physicochemical
interactions between the small molecule and
the macromolecular target (Coupez and Lewis
2006; Sousa et al. 2006). The docking score
can be construed as a surrogate for the energy
of interaction between the target and the
small molecule, and in some cases is provided
in terms of measures such as the log of the
dissociation constant for inhibitor binding
(Ki) or kilocalories per mole that may be
directly compared with binding experiments.
Comparison of these scores or computed
interaction energies for a library of chemicals
provides a means for ordering the molecules
by their capacity to interact with the macro-
molecular target. Chemicals with the best
scores are most likely to interact with the tar-
get and are selected as subjects for further
study. It is important to consider more than
just a single pose with the best score because
there are likely several local minimum energy
poses in the interaction profile and a variety
of highly ranked poses (Coupez and Lewis
2006; Sousa et al. 2006).
As is the case for the design of novel
pharmaceutical agents, the successful applica-
tion of docking methods to problems in
chemical toxicity depends on the identiﬁcation
and availability of the crystal structures of the
macromolecular targets or similar proteins. A
variety of structures are available for macro-
molecular targets that are known to be linked
to the adverse effects of environmental chemi-
cals, and their number is continually increasing
(Hu et al. 2005; Wang et al. 2005). However,
simulations of the interaction between small
molecules and a macromolecular target for the
purposes of drug discovery versus toxicity
screening have distinct differences and, thus,
present distinct challenges: a) the focus on dif-
ferent (yet overlapping) regions of chemical
space; b) the strength of interaction between a
small molecule and macromolecular targets;
and c) the ultimate purpose of the virtual
screening results.
Figure 2 is an approximate depiction of the
chemical space for nonpharmaceutical com-
mercial chemicals versus druglike chemicals in
three selected dimensions of physicochemical
characteristics. Viable drug candidates are typi-
cally those that have a strong interaction with a
speciﬁc target, have good bioavailability, and
are readily metabolized to inactive compounds
and cleared from the system, in other words,
compounds that have speciﬁc absorption, dis-
tribution, metabolism, excretion, and toxicity
(ADMET) profiles and prescribed chemical
properties. In contrast, environmental chemi-
cals span a considerably larger chemical space
and tread into “undesirable” property space
from an ADMET perspective (too small, too
insoluble, too reactive, etc.). They can also
elicit adverse biologic effects from both strong
and weak interactions with targets and in both
a speciﬁc and nonspeciﬁc manner. Weak inter-
actions and nonspeciﬁcity are also important
aspects of pharmaceutical development because
some side effects might arise from unintended
binding to secondary targets (Ekins 2004;
Rabinowitz et al.
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Figure 1. An overview of molecular modeling in computational toxicology. Abbreviations: QSAR, quantita-
tive structure–activity relationship; QSPR, quantitative structure–property relationship. After the identiﬁca-
tion of a putative toxicant and target complexes (yellow sphere), the target structure (red spheres) is
either experimentally determined or modeled based on structures with known sequence identity.
Cheminformatics approaches and molecular docking (green spheres) can be used to obtain information
about the putative toxicant (overlap of red and green spheres) and predict the desired properties, such as
target-speciﬁc binding afﬁnity and molecular modes of binding. Mathematical and visual analytics, such as
hierarchical clustered heat maps or target-speciﬁc linkage maps, can yield knowledge that is chemical-
class specific or target specific. Experimental guidance (blue arrow) optimizes this virtual screening
approach.
Structural bioinformatics
CheminformaticsJi et al. 2006). In addition, some environmen-
tal chemicals are produced and disposed of in
signiﬁcantly larger quantities than are pharma-
ceuticals and, hence, may present inadvertent
human hazards over a long-term, low-dose
exposure scenario. This is particularly the case
if they are more chemically stable and persis-
tent (i.e., resistant to metabolism), are poten-
tially as bioavailable as drug candidates, or act
through common pathways (thus posing
cumulative effects) even if their individual tar-
get-speciﬁc interactions are much weaker than
drugs or endogenous chemicals. Hence, evalu-
ating the relative effectiveness of chemicals that
bind more weakly or to multiple targets less
speciﬁcally presents a greater challenge experi-
mentally and computationally than does the
discovery of novel pharmaceutical leads.
Scoring functions in molecular modeling
methods are typically optimized to identify
chemicals that bind best to the target.
Another significant difference between
pharmaceutical optimization and assessing the
chemical toxicity of environmental chemicals
is the purpose of an initial screen of a chemical
library. For the pharmaceutical industry, the
purpose of the initial screen for finding new
drug candidates is to limit the number of
chemicals that proceed to the next (more
expensive) phase of testing while increasing
the ratio of chemicals likely to become drugs
to those likely to be inactive (i.e., increasing
the “hit rate”). As long as the hit rate becomes
significantly improved by this process, the
exclusion of some active chemicals is a reason-
able cost. In contrast, the purpose of an initial
screen of environmental chemicals is to maxi-
mize the chance that active chemicals advance
to the next phase of testing while eliminating
as many inactive chemicals as possible. Given
this objective and the corresponding uncer-
tainties in assessing “potency” or activity based
solely on computed scoring functions, the goal
is to discover all or almost all of the agents
having the potential to interact with the tar-
get, even those in signiﬁcantly lower binding
afﬁnity domains than the endogenous or puta-
tive cognate ligand for the receptor. Thus,
minimizing the number of false negatives is
critical when screening environmental chemi-
cals because the expectation is that positive
chemicals will be tested later in an experimen-
tal protocol. A toxicity screen should not reject
a compound (i.e., classify as inactive or safe)
that has a weak afﬁnity for a target or multiple
targets without considering its ADMET prop-
erties, persistence, and chance of exposure.
Obtaining activity signatures from receptor
affinity profiles of compounds not intended
for therapeutic application may become an
important aspect of multilevel screening pro-
grams that include measured biologic proper-
ties, such as ToxCast (Dix et al. 2007).
Enrichment and False
Negatives
Figure 3 shows two hypothetical data scenar-
ios derived from computational docking
experiments using the same library of chemi-
cals against a model target. The difference
between the two sets arises either from choos-
ing different docking score thresholds between
predicted active and inactive chemicals or
from using different scoring functions. For
this example, definitive (ideal) experimental
tests determine that 5% of the chemicals are
active and 95% are inactive relative to the
macromolecular target of interest. Scenario A
has 89% of the chemicals classiﬁed correctly,
whereas scenario B has only 55% of the chem-
icals classiﬁed correctly. The enrichment factor
for scenario A is 4 because 20% of the chemi-
cals selected for further testing (i.e., screened
positive) will prove to be positive, whereas the
enrichment factor for scenario B is only 2.
However, the type II error for scenario A is
0.6, whereas it is 0.0 for scenario B.
The screening method used for scenario A
appears to be better by many measures and is
an appropriate approach if the goal is to dis-
cover novel pharmaceutical leads. On the
other hand, the screening method used for
scenario B is more appropriate when screening
chemicals for potential toxicity. Scenario B
will carry many more chemicals to the next
phase of testing, but the negatives are true
negatives. Chemicals identified by this pre-
screen as negative will have a lower priority for
continued testing and perhaps will not be
tested in any other manner for effects at this
particular target.
This discussion addresses the challenges in
using current docking methods for assessing
chemical toxicity. The methods that are cur-
rently available for computational molecular
docking were developed for drug discovery
and therefore are optimized to screen large
chemical databases to find the most active
molecules and increase the enrichment factor.
Molecular modeling for prioritizing bioassays
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Figure 2. Plot of environmental anthropogenic compounds and registered pharmaceuticals subject to a
Lipinski druglike ﬁlter. The axes represent three physicochemical characteristics for each compound: total
polar surface area, partition coefﬁcient (log P) between octanol and water, and fraction halogenated. The
environmental compounds are the high-production-volume chemicals (Wolf et al. 2006), and the registered
pharmaceuticals are the FDAMDD [FDA (Food and Drug Administration) maximum (recommended) daily
dose] set from the DSSTox (Distributed Structure-Searchable Toxicity) database (Matthews et al. 2005).
Percent halogen
Log P (octanol/water)
Topologic
polar surface area (A3)
Registered pharmaceuticals
High-production-volume chemicals
Figure 3. Illustration of type II errors and enrich-
ment factors in chemical screening. The statistical
“type II error” is the ratio of the number of false
negatives to the sum of false negatives and true
positives. The “enrichment factor” is the ratio of
the true positive rate of the screen (the number of
true positives divided by the number of true posi-
tives plus false positives) to the ideal positive rate
of the chemical library (the number of positive
chemicals in the library divided by the number of
chemicals in the library).
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+−Some false negatives are not an important
concern as long as the enrichment rate is sig-
niﬁcantly increased. In contrast, a screen for
assessing chemicals for potential toxicity often
deals with a smaller database of chemicals (the
chemicals encountered in the environment)
and must be capable of identifying chemicals
with much lower affinities than the natural
ligands. Therefore, scoring functions and/or
methods for delineating active chemicals from
inactive chemicals must be explored and bet-
ter understood in the context of environmen-
tal chemicals, and may involve computational
methods that are more accurate but computa-
tionally intensive.
Virtual Screening of Chemicals
The usual approach for virtual screening of
chemicals for toxicity is to screen a database of
chemicals for each chemical’s capacity to inter-
act with a single macromolecular target and
initiate a single mode of chemical toxicity. A
virtual screen that is receptor specific pro-
duces a score vector where each element rep-
resents the interaction of that receptor with a
different chemical entity. Inverting the prob-
lem so that the vector now contains elements
that represent the capacity of a single chemi-
cal to interact with each of a series of targets
allows the most likely targets and, therefore,
the most likely modes of toxicity for a speciﬁc
chemical to be identified. A matrix is pro-
duced by interrogating a library of targets
with a database of chemicals. The relation-
ships among the elements in this matrix have
the potential to yield additional insights, such
as receptor cross-talk or multiple modes of
biologic potency (Macchiarulo et al. 2004),
and modes of sequestration (Perry et al.
2004). A combination of these computation-
ally derived data and experimentally derived
data can be data-mined to extract patterns and
associations. These associations can provide
additional knowledge for assessing the hazards
of chemicals and chemical mixtures or be used
to improve prediction tools in the context of
toxicity such as scoring functions for molecu-
lar docking calculations.
For some targets in the library, other inter-
actions in addition to those included in dock-
ing algorithms must be considered. For
instance, modes of toxicity have been identiﬁed
that require covalent interactions between the
toxicant and the target (Zhou et al. 2005) or
that necessitate the redistribution of charge in
both the toxicant and the target (Pardo et al.
1993). These interactions involve the elec-
tronic structure of both the putative toxicant
and target molecules and, hence, require some
level of quantum chemistry. However, most
current docking methods include only classical
interactions. One approach is to use molecular
docking to determine the structure of com-
plexes, and then to calculate the short-range
interactions with quantum chemistry methods.
A few attempts have been made in recent
years to build essential quantum effects
directly into molecular docking calculations,
such as quantum polarized ligand docking
(Cho et al. 2005).
In addition, to take into account the
known or hypothesized biotransformation
products during the molecular docking calcu-
lations, each constituent must be included as
separate chemical entities in the docking cal-
culations. Computational tools already exist
for predicting metabolites (Jolivette and Ekins
2007), so docking calculations could be
improved by networking with metabolism
prediction models.
Another application for virtual screening is
predicting prospective targets for a particular
chemical and its metabolites using inverse
docking strategies. In drug discovery, this
approach can identify potential alternate uses
for drug candidates or predict side effects of
pharmaceuticals that might arise from unin-
tended interactions with other targets (i.e., off-
target effects), thus producing adverse
outcomes. As an element in a toxicity screen
for environmental chemicals, inverse docking
tools can be used to guide experimental test-
ing. Inverse docking can help focus efforts and
lead to a reduction in the use of resources as
well as the time required for a hazard or risk
assessment. Some attempts at inverse docking
methods have arisen in recent years (Ekins
2004; Ji et al. 2006), although these methods
still face some limitations that prevent their
more general use in virtual screenings. Inverse
docking strategies could become a more viable
resource as further target crystal structures
become available and molecular docking
methods are improved, and in conjunction
with systems biology methods such as pro-
teomics and genomics (Loging et al. 2007).
Conclusions
Computational molecular modeling methods
aid the risk assessment process by providing a
rational approach for some extrapolations in
the evaluation of chemical hazard. For
instance, when elements of a data set required
for evaluating the potential hazard of a chemi-
cal are unavailable and inferences can be made
based on interactions with putative targets,
molecular modeling can be used to simulate
the relevant missing information. Both ligand-
and structure-based molecular modeling
methods used in pharmaceutical discovery can
be adapted to provide this type of simulated
data. However, because of the greater diversity
of chemical space and binding affinity
domains being considered and the differences
in the strategic application of the results (the
need to minimize false negatives), these
molecular modeling strategies require addi-
tional considerations when assessing chemical
hazards. Molecular docking of potential envi-
ronmental chemicals to putative macromolecu-
lar targets for toxicity provides a measure of
their capacity to interact and hence is an aid in
the (pre)screening process for speciﬁc modes of
toxicity. These results provide a rationale for
developing further, more complete testing
strategies.
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